Physician profile
Mohammed Asgar
NPI 1023004587
$480.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120.27 | 2022-2023 | Verquvo |
| Nuvasive, INC. | $85.57 | 2023 | Pulse |
| Abbvie INC. | $67.12 | 2022-2023 | Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $31.93 | 2022 | |
| Organogenesis INC. | $27.73 | 2023 | Puraply |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.15 | 2022 | |
| Sk Life Science, INC. | $24.66 | 2023 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $24.03 | 2023 | Rexulti |
| Global Blood Therapeutics, INC. | $21.94 | 2022 | |
| Hikma Pharmaceuticals USA | $17.28 | 2022 | |
| Amgen INC. | $16.61 | 2023 | Repatha, Otezla |
| Medline Industries LP | $16.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Asgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.